Inhibikase Therapeutics (IKT) Competitors $1.91 -0.05 (-2.55%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. ORIC, GHRS, TSHA, KROS, BCYC, IOVA, UPB, VECT, MNMD, and DNTHShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include ORIC Pharmaceuticals (ORIC), GH Research (GHRS), Taysha Gene Therapies (TSHA), Keros Therapeutics (KROS), Bicycle Therapeutics (BCYC), Iovance Biotherapeutics (IOVA), Upstream Bio (UPB), VectivBio (VECT), Mind Medicine (MindMed) (MNMD), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors ORIC Pharmaceuticals GH Research Taysha Gene Therapies Keros Therapeutics Bicycle Therapeutics Iovance Biotherapeutics Upstream Bio VectivBio Mind Medicine (MindMed) Dianthus Therapeutics ORIC Pharmaceuticals (NASDAQ:ORIC) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Does the MarketBeat Community prefer ORIC or IKT? ORIC Pharmaceuticals received 67 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. Likewise, 76.00% of users gave ORIC Pharmaceuticals an outperform vote while only 75.00% of users gave Inhibikase Therapeutics an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes7676.00% Underperform Votes2424.00% Inhibikase TherapeuticsOutperform Votes975.00% Underperform Votes325.00% Do insiders and institutionals have more ownership in ORIC or IKT? 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 6.8% of ORIC Pharmaceuticals shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ORIC or IKT? ORIC Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Is ORIC or IKT more profitable? ORIC Pharmaceuticals' return on equity of -44.54% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -44.54% -40.72% Inhibikase Therapeutics N/A -350.63%-201.82% Does the media prefer ORIC or IKT? In the previous week, ORIC Pharmaceuticals had 19 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 20 mentions for ORIC Pharmaceuticals and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.73 beat ORIC Pharmaceuticals' score of 0.75 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend ORIC or IKT? ORIC Pharmaceuticals currently has a consensus price target of $19.17, suggesting a potential upside of 98.21%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 240.31%. Given Inhibikase Therapeutics' higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation & earnings, ORIC or IKT? Inhibikase Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.87-5.17Inhibikase Therapeutics$260K546.13-$19.03M-$2.67-0.72 SummaryORIC Pharmaceuticals beats Inhibikase Therapeutics on 10 of the 16 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$141.99M$3.12B$5.61B$19.87BDividend YieldN/A1.57%5.28%3.83%P/E Ratio-0.7232.9027.1435.60Price / Sales546.13466.20411.8343.81Price / CashN/A168.6838.2517.51Price / Book1.073.427.064.85Net Income-$19.03M-$72.35M$3.23B$1.02B7 Day Performance-2.55%7.27%2.67%1.94%1 Month Performance-12.79%17.53%8.82%3.02%1 Year Performance20.89%-17.27%31.44%9.87% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.4971 of 5 stars$1.91-2.6%$6.50+240.3%+22.9%$141.99M$260K-0.726Positive NewsORICORIC Pharmaceuticals3.8968 of 5 stars$8.47+3.7%$19.17+126.3%+17.2%$602.12MN/A-4.6580Trending NewsAnalyst RevisionHigh Trading VolumeGHRSGH Research1.7685 of 5 stars$11.56-3.9%$30.43+163.2%+14.9%$601.44MN/A-14.6310Analyst RevisionTSHATaysha Gene Therapies3.8441 of 5 stars$2.79+3.0%$7.29+161.1%-28.8%$598.91M$7.22M4.43180Analyst ForecastAnalyst RevisionKROSKeros Therapeutics3.6506 of 5 stars$14.66+3.6%$37.00+152.4%-71.2%$595.42M$214.71M-2.81100Analyst DowngradeBCYCBicycle Therapeutics3.3636 of 5 stars$8.55+4.0%$25.00+192.4%-63.1%$592.12M$25.72M-2.60240News CoverageAnalyst RevisionIOVAIovance Biotherapeutics4.5246 of 5 stars$1.76+0.6%$13.30+655.7%-74.0%$587.72M$212.68M-1.18500Trending NewsUPBUpstream Bio1.9393 of 5 stars$10.66+15.5%$56.50+430.0%N/A$573.44M$2.30M0.0038High Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeMNMDMind Medicine (MindMed)1.9812 of 5 stars$7.48+3.0%$25.11+235.7%-1.7%$565.14MN/A-3.3140News CoveragePositive NewsAnalyst RevisionDNTHDianthus Therapeutics1.5558 of 5 stars$17.53+0.8%$53.00+202.3%-24.4%$563.77M$6.52M-7.0180Positive NewsAnalyst Revision Related Companies and Tools Related Companies ORIC Alternatives GHRS Alternatives TSHA Alternatives KROS Alternatives BCYC Alternatives IOVA Alternatives UPB Alternatives VECT Alternatives MNMD Alternatives DNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
